Leap Therapeutics, Inc.
NASDAQ: LPTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Douglas E. Onsi
- Employees
- 52
- Headquarters
- Cambridge, United States
- IPO year
- 2017
- Market cap
- $31.9M
- Website
- https://www.leaptx.com
Loading LPTX…
Loading profile data…Frequently asked questions about LPTX
What does Leap Therapeutics, Inc. (LPTX) do?
Leap Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing treatments for various cancers. At the forefront of its pipeline is DKN-01, a monoclonal antibody designed to block Dickkopf-related protein 1 (DKK1). This investigational therapy is currently undergoing several clinical trials, targeting a range of malign...
Where does LPTX trade?
Leap Therapeutics, Inc. (LPTX) trades on the NASDAQ Global Market.
What sector is LPTX in?
Leap Therapeutics, Inc. (LPTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Leap Therapeutics, Inc.?
Douglas E. Onsi is the chief executive officer of Leap Therapeutics, Inc. (LPTX).
Where is Leap Therapeutics, Inc. headquartered?
Leap Therapeutics, Inc. is headquartered in United States.
Does LPTX pay a dividend?
Leap Therapeutics, Inc. (LPTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did LPTX go public?
Leap Therapeutics, Inc. (LPTX) completed its initial public offering in 2017.